International journal of surgery (London, England) · 2025
Efficacy and safety of immune checkpoint inhibitors in hepatocellular carcinoma: a comprehensive umbrella review of meta-analyses.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Zhou Ying, Yao Ming-Hong, Ma Ji, Wen Tian-Fu, Zhang Xiao-Yun
Аннотация
OBJECTIVE: To summarize and assess the existing evidence on the effectiveness and safety of immune checkpoint inhibitors (ICIs) treatments in patients diagnosed with hepatocellular carcinoma (HCC).
DESIGN: An umbrella review encompassing current meta-analyses reporting clinical effectiveness or safety outcomes of ICIs.
DATA SOURCES: PubMed, Web of Science, Embase, the Cochrane Systematic Reviews Database, and reviewed reference sections of relevant research articles.
STUDY SELECTION: We included all systematic reviews with meta-analyses of observational or interventional studies evaluating ICIs in patients with HCC. The patient cohorts comprised adults with HCC, including both those with advanced disease and those receiving neoadjuvant therapy for resectable tumors.
RESULTS: Fifty-four meta-analyses (covering 166 direct comparisons and over 35,000 patients) were included. High-quality evidence demonstrated that ICI plus tyrosine kinase inhibitor (TKI) significantly improved overall survival (HR 0.58, 95% CI, 0.49-0.70) and progression-free survival (HR 0.58, 95% CI, 0.51-0.67), and increased objective response rates (OR 3.17, 95% CI, 2.21-4.54), compared with TKI monotherapy. Triple combination therapy (ICI + TKI + locoregional therapy) yielded the largest absolute gains in survival (HR 0.48, 95% CI, 0.36-0.64) and tumor response, but evidence was of moderate quality due to protocol heterogeneity. Subgroup analyses indicated greater benefits in hepatitis B-related HCC and male patients. ICIs demonstrated a manageable safety profile, with increased risks of hypertension and thyroid dysfunction, but no significant excess in most grade ≥3 toxicities. Only 11.1% of meta-analyses were of high methodological quality; just 24.4% of statistically significant outcomes were graded as high quality, and all evidence was class IV by sample size.
CONCLUSION: ICI-based regimens, particularly ICI + TKI doublets, offer substantial survival and tumor response benefits for HCC with manageable toxicity. Triple and conversion strategies are promising but require further high-quality randomized trials. Current recommendations are limited by the generally low quality and size of existing meta-analyses, underscoring the need for rigorous primary studies and robust future evidence syntheses.
DESIGN: An umbrella review encompassing current meta-analyses reporting clinical effectiveness or safety outcomes of ICIs.
DATA SOURCES: PubMed, Web of Science, Embase, the Cochrane Systematic Reviews Database, and reviewed reference sections of relevant research articles.
STUDY SELECTION: We included all systematic reviews with meta-analyses of observational or interventional studies evaluating ICIs in patients with HCC. The patient cohorts comprised adults with HCC, including both those with advanced disease and those receiving neoadjuvant therapy for resectable tumors.
RESULTS: Fifty-four meta-analyses (covering 166 direct comparisons and over 35,000 patients) were included. High-quality evidence demonstrated that ICI plus tyrosine kinase inhibitor (TKI) significantly improved overall survival (HR 0.58, 95% CI, 0.49-0.70) and progression-free survival (HR 0.58, 95% CI, 0.51-0.67), and increased objective response rates (OR 3.17, 95% CI, 2.21-4.54), compared with TKI monotherapy. Triple combination therapy (ICI + TKI + locoregional therapy) yielded the largest absolute gains in survival (HR 0.48, 95% CI, 0.36-0.64) and tumor response, but evidence was of moderate quality due to protocol heterogeneity. Subgroup analyses indicated greater benefits in hepatitis B-related HCC and male patients. ICIs demonstrated a manageable safety profile, with increased risks of hypertension and thyroid dysfunction, but no significant excess in most grade ≥3 toxicities. Only 11.1% of meta-analyses were of high methodological quality; just 24.4% of statistically significant outcomes were graded as high quality, and all evidence was class IV by sample size.
CONCLUSION: ICI-based regimens, particularly ICI + TKI doublets, offer substantial survival and tumor response benefits for HCC with manageable toxicity. Triple and conversion strategies are promising but require further high-quality randomized trials. Current recommendations are limited by the generally low quality and size of existing meta-analyses, underscoring the need for rigorous primary studies and robust future evidence syntheses.